• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IMCR

    Immunocore Holdings plc

    Subscribe to $IMCR
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: https://www.immunocore.com

    Recent Analyst Ratings for Immunocore Holdings plc

    DatePrice TargetRatingAnalyst
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    10/24/2024$24.00Sell
    UBS
    10/7/2024Buy → Neutral
    Guggenheim
    4/29/2024$74.00Outperform
    Leerink Partners
    11/20/2023$60.00Overweight
    JP Morgan
    11/2/2023Overweight
    Cantor Fitzgerald
    10/31/2023$84.00Outperform
    Robert W. Baird
    9/13/2023$75.00Buy
    Needham
    9/13/2023$9.00 → $22.00Neutral → Overweight
    JP Morgan
    See more ratings

    Immunocore Holdings plc Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to present at upcoming investor conferences

      Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April.                   Kempen Life Sciences Conference                  1x1 and small group meetings: Thursday, April 3, 2025                   Needham Virtual Healthcare Conferen

      4/2/25 8:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

      Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically impr

      3/10/25 3:00:00 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to present at upcoming investor conferences

      (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in March.                   TD Cowen 45th Annual Healthcare Conference                  Presentation: Tuesday, March 4, 2025, at 3:10 p.m. EST                   Barclays 27th Annual Global Healthcare Conference                  Fireside Chat: Tue

      3/3/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

      KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025 and Phase

      2/26/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

      (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio u

      2/19/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

       Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE) Presenting initial HIV Phase 1 MAD data in the first quarter 2025 Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic dermatitis anno

      1/10/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

      Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation is scheduled for Wednesday, January 15, 2025, at 8:15 a.m. Pacific Standard Time (PST).

      1/6/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

      1/2/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

      Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life   The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with advanced solid tumors that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 23 December 2024) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delive

      12/23/24 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunocore Holdings plc Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Pao William

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:31:08 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pao William

      3 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:29:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF HR OFFICER St Leger Tina Amber

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/19/25 4:20:37 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by SVP, FINANCE & CAO Goll John

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/19/25 4:19:12 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by HEAD OF R&D Berman David M

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/19/25 4:18:07 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Jallal Bahija

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/19/25 4:17:09 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Baker Bros. Advisors Lp

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      5/29/24 4:53:39 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Krishana Ranjeev

      3 - Immunocore Holdings plc (0001671927) (Issuer)

      5/29/24 4:46:28 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Baker Bros. Advisors Lp claimed ownership of 1,515,318 units of American Depositary Shares (SEC Form 3)

      3 - Immunocore Holdings plc (0001671927) (Issuer)

      5/29/24 4:43:38 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunocore Holdings plc Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:28:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:22:39 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 6:40:08 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/12/24 4:47:03 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/8/24 10:52:38 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunocore Holdings plc

      SC 13G - Immunocore Holdings plc (0001671927) (Subject)

      9/10/24 1:49:30 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunocore Holdings plc

      SC 13G - Immunocore Holdings plc (0001671927) (Subject)

      3/11/24 8:19:04 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Immunocore Holdings plc (Amendment)

      SC 13D/A - Immunocore Holdings plc (0001671927) (Subject)

      3/7/24 9:45:57 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunocore Holdings plc (Amendment)

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      2/14/24 2:09:32 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunocore Holdings plc

      SC 13G - Immunocore Holdings plc (0001671927) (Subject)

      2/14/24 10:03:05 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunocore Holdings plc Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immunocore downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously

      12/13/24 8:04:38 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore downgraded by Mizuho with a new price target

      Mizuho downgraded Immunocore from Outperform to Neutral and set a new price target of $38.00 from $72.00 previously

      11/11/24 7:41:04 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Immunocore with a new price target

      UBS initiated coverage of Immunocore with a rating of Sell and set a new price target of $24.00

      10/24/24 6:22:17 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore downgraded by Guggenheim

      Guggenheim downgraded Immunocore from Buy to Neutral

      10/7/24 8:32:04 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Leerink Partners initiated coverage on Immunocore with a new price target

      Leerink Partners initiated coverage of Immunocore with a rating of Outperform and set a new price target of $74.00

      4/29/24 7:22:40 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on Immunocore with a new price target

      JP Morgan resumed coverage of Immunocore with a rating of Overweight and set a new price target of $60.00

      11/20/23 7:31:24 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Immunocore

      Cantor Fitzgerald initiated coverage of Immunocore with a rating of Overweight

      11/2/23 7:08:49 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Immunocore with a new price target

      Robert W. Baird initiated coverage of Immunocore with a rating of Outperform and set a new price target of $84.00

      10/31/23 6:51:58 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on Immunocore with a new price target

      Needham initiated coverage of Immunocore with a rating of Buy and set a new price target of $75.00

      9/13/23 7:57:29 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore upgraded by JP Morgan with a new price target

      JP Morgan upgraded Immunocore from Neutral to Overweight and set a new price target of $22.00 from $9.00 previously

      9/13/23 7:49:08 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunocore Holdings plc Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunocore Holdings plc SEC Filings

    See more
    • SEC Form S-8 filed by Immunocore Holdings plc

      S-8 - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 4:38:41 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 7:33:58 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Immunocore Holdings plc

      10-Q - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 7:00:46 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Immunocore Holdings plc

      DEF 14A - Immunocore Holdings plc (0001671927) (Filer)

      4/4/25 6:05:50 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Immunocore Holdings plc

      PRE 14A - Immunocore Holdings plc (0001671927) (Filer)

      3/24/25 4:24:14 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore Holdings plc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Immunocore Holdings plc (0001671927) (Filer)

      3/17/25 8:18:24 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B7 filed by Immunocore Holdings plc

      424B7 - Immunocore Holdings plc (0001671927) (Filer)

      3/17/25 8:04:12 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POSASR filed by Immunocore Holdings plc

      POSASR - Immunocore Holdings plc (0001671927) (Filer)

      3/17/25 6:48:19 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Immunocore Holdings plc

      144 - Immunocore Holdings plc (0001671927) (Subject)

      3/14/25 5:08:58 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Immunocore Holdings plc (0001671927) (Filer)

      3/10/25 4:17:36 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunocore Holdings plc Leadership Updates

    Live Leadership Updates

    See more
    • Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

      1/2/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunocore Appoints Siddharth Kaul to its Board of Directors

      Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s

      6/9/22 7:45:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Immunocore Holdings plc Financials

    Live finance-specific insights

    See more
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

      KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025 and Phase

      2/26/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

      (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio u

      2/19/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports third quarter financial results and provides a business update

      Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md

      11/6/24 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports second quarter financial results and provides a business update

      KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing, following conversion of Phase 2/3 trial – expect to complete enrollment in 1H 2026 Registrational Phase 3 (PRISM-MEL-301) evaluating brenetafusp + nivolumab in first-line cutaneous melanoma started randomization Presented Phase 1 data of brenetafusp in late-line cutaneous melanoma patients at ASCO 2024; late-line high-grade serous ovarian data to be presented at ESMO 2024 Conference call today, August 8, 2024 at 8:00 AM ET, 1:00 PM BST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILL

      8/8/24 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

      Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 August 2024) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 8, 2024. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to

      8/1/24 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

      Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in late-line cutaneous melanoma demonstrated promising disease control (partial response and stable disease), progression free survival (PFS), and ctDNA molecular response Clinical activity was enriched in PRAME positive patients with 58% disease control rate and 4.2 months median PFS Peripheral blood T cell fitness was associated with increased brenetafusp clinical activity and was higher in earlier lines of therapy Brenetafusp is well tolerated as monotherapy and

      5/31/24 4:05:00 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with

      5/8/24 7:00:00 AM ET
      $BMY
      $IMCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Immunocore announces upcoming presentation and posters at ASCO 2024

      Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, will present Phase 1 expansion data for brenetafusp (IMC-F106C), the first off-the-shelf ImmTAC therapy

      4/24/24 10:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

      Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) with nivolumab in registrational Phase 3 first-line advanced cutaneous melanoma trial; PRISM-MEL301 trial to start in 1Q 2024 Multiple clinical readouts expected to start in 2Q 2024 for IMC-F106

      2/28/24 7:34:03 AM ET
      $BMY
      $IMCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)